Rice-Boucher et al., 2025 - Google Patents
In vivo targeted gene delivery using Adenovirus-antibody molecular glue conjugatesRice-Boucher et al., 2025
View HTML- Document ID
- 6435296563492837480
- Author
- Rice-Boucher P
- Kashentseva E
- Dmitriev I
- Guo H
- Tremblay J
- Shoemaker C
- Curiel D
- Lu Z
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
Safe and efficient nucleic acid delivery to targeted cell populations remains a significant unmet need in the fields of cell and gene therapy. Towards this end, we pursued Adenoviral vectors genetically modified with the “DogTag” molecular glue peptide, which forms a …
- 238000001727 in vivo 0 title abstract description 38
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamilton et al. | In vivo human T cell engineering with enveloped delivery vehicles | |
| Kanerva et al. | Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses | |
| EP0614486B1 (en) | Targeted delivery of virus vector to mammalian cells | |
| JP7048494B2 (en) | Conditional active chimeric antigen receptor for modified T cells | |
| Uusi-Kerttula et al. | Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications | |
| Zhu et al. | A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells | |
| US20030175973A1 (en) | Targeted recombinant viral vectors | |
| Gleiter et al. | Coupling of antibodies via protein Z on modified polyoma virus‐like particles | |
| MX2015003616A (en) | Fc-free antibodies comprising two fab-fragments and methods of use. | |
| JP2022513586A (en) | Anti-LIV1 immune cell cancer therapy | |
| KR20140004174A (en) | Compositions and methods for treating cancer | |
| Prill et al. | Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo | |
| JP7668261B2 (en) | Cells and uses thereof for improved immunotherapy - Patents.com | |
| Kaliberov et al. | Adenoviral targeting using genetically incorporated camelid single variable domains | |
| Wang et al. | A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route | |
| Kim et al. | A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: The safety profile of Ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients | |
| Messerschmidt et al. | Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling | |
| Kuroki et al. | Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer | |
| Van Erp et al. | Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein | |
| Lv et al. | Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2 | |
| Rice-Boucher et al. | In vivo targeted gene delivery using Adenovirus-antibody molecular glue conjugates | |
| Rice-Boucher et al. | In-vivo-targeted gene delivery using adenovirus-antibody site-specific covalent conjugates | |
| Situ et al. | Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules | |
| WO2022148491A1 (en) | Assembled protein element and use thereof | |
| Jeon et al. | Targeted cancer therapy using fusion protein of TNFα and tumor-associated fibronectin-specific aptide |